Clinical Evidence: Heart Attack and Stroke Risk Reduction The SUSTAIN-6 trial, which followed over 3,000 people with type 2 diabetes and existing heart disease or high cardiovascular risk, found that semaglutide reduced the combined risk of heart attack, stroke, and cardiovascular death by 26% compared to placebo
Larger, well-controlled clinical trials are still needed to confirm its efficacy and safety as a therapeutic treatment before any recommendations can be made
Por otro lado, promueve de forma directa el desarrollo de ateroesclerosis (3) y desencadena un aumento de las citocinas inflamatorias, especialmente de la interleucina-6, lo que provoca un estado inflamatorio crnico, aumentando la morbilidad y mortalidad por enfermedades cardiovasculares (4)
side effects experienced
You can use the following link to check if your insurance plan covers Wegovy
Wegovys label lists adverse mental health side effects, yet Ozempics label does not